TL;DR — Apigenin is the flavone behind chamomile's calming reputation, and separately, a 2013 discovery that it inhibits CD38 — the enzyme that consumes NAD+ as we age — in mouse liver and cell culture. Those are two different evidence stories: the sedative/anxiolytic effect has real human RCT support (from whole chamomile extract, not isolated apigenin), while the NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary →-preservation and SASPSenescence-Associated Secretory Phenotype — the inflammatory cocktail of cytokines, proteases, and growth factors secreted by senescent (zombie) cells. Full glossary →-suppression story that drives most of the longevity interest is still preclinical. No trial has dosed isolated apigenin in humans and measured NAD+, inflammation, or any aging endpoint. Tier C, and the gap between mouse-liver CD38 data and a human supplement claim is the single most important thing to hold onto here.
What apigenin does (and why the CD38 story matters)
Apigenin (4′,5,7-trihydroxyflavone) is a flavone concentrated in chamomile flowers, parsley, celery, and dried oregano — chamomile tea's traditional reputation as a mild sedative is essentially an apigenin story, since apigenin binds the benzodiazepine site on GABA-A receptors. That's the older, better-established pharmacology.
The newer longevity interest traces to a single 2013 paper: Escande and colleagues screened flavonoids for CD38 inhibition and found apigenin blocks CD38, the cell-surface enzyme that degrades NAD+ and rises with age and inflammation. In obese mice, apigenin treatment raised liver NAD+, increased SIRT1/SIRT3 deacetylase activity, and improved glucose tolerance and lipid metabolism. This is the same CD38-NAD+ axis that motivates NMN and NR — but apigenin's proposed contribution is different: instead of adding NAD+ precursor, it targets the enzyme that drains the pool.
Primary hallmarks targeted: Chronic inflammation · Cellular senescence
Escande et al. 2013 (PMID 23172919, Diabetes 62(4):1084–1093): apigenin inhibited CD38 in vitro and, in diet-induced obese mice, raised hepatic NAD+, increased SIRT1/SIRT3 activity, and improved glucose tolerance and lipid profiles. This is the foundational paper for apigenin's NAD+ claim — and it is a rodent and cell-culture study. No human trial has replicated CD38 inhibition or NAD+ elevation from oral apigenin.
Mechanism — CD38/NAD+, NF-κB/NLRP3, and SASP suppression are three separate evidence bases
| Pathway | Mechanism | Evidence base | Hallmark link |
|---|---|---|---|
| CD38 inhibition → NAD+ preservation | Blocks the NADase that competes with sirtuinsLongevity-associated enzymes that repair DNA, regulate metabolism, and control inflammation. Full glossary →/PARPs for NAD+ | Mouse liver + in vitro (PMID 23172919) | — |
| NF-κB / NLRP3 suppression | Blocks IκB kinase and NLRP3 inflammasome assembly, lowering IL-1β release from monocytes/macrophages | Human monocyte and macrophage cell culture (PMID 39840045) | Chronic inflammation |
| SASP suppression | Suppresses IL-1α→IRAK1/IRAK4→p38-MAPK→NF-κB signaling in senescent fibroblasts, cutting CXCL10 (IP-10) secretion | Human fibroblast cell culture, 3 senescence-induction models (PMID 28378188) | Cellular senescence |
| GABA-A benzodiazepine-site binding | Mild anxiolytic/sedative effect | Human RCTs of whole chamomile extract (PMID 19593179, 21939549) | — |
← Swipe for more columns →
These four mechanisms don't add up to one coherent human trial — they're four separate literatures (rodent metabolism, human immune cell culture, human fibroblast culture, and whole-plant-extract clinical trials) that happen to converge on the same molecule. That's a real and interesting convergence, but it is not the same as a dedicated apigenin-in-humans dataset.
When apigenin is worth adding
Apigenin earns a place when two or more apply:
- You want a mild, evening anxiolytic/sedative and are comfortable that the human RCT evidence is for chamomile extract, not isolated apigenin at supplement doses
- You're already running an NAD+ stack (NMN or NR) and want a CD38-inhibition rationale layered on top, understanding this is mouse-liver evidence extrapolated to humans
- You want low-cost SASP-suppression coverage alongside better-evidenced senescence tools, not in place of them
Skip or defer if you're looking for a proven NAD+ booster on its own merits (NMN/NR have the human RCT data apigenin lacks), or if you're already on a benzodiazepine, other GABAergic sedative, or alcohol regularly.
Evidence summary
| Study | Design | Key outcome | Tier |
|---|---|---|---|
| Escande 2013 (PMID 23172919) | Mouse (diet-induced obesity) + in vitro | ↑ hepatic NAD+, ↑ SIRT1/SIRT3 activity, improved glucose/lipid handling | C (preclinical) |
| Lauritzen 2024 (PMID 39840045, Front Immunol) | Human monocyte/macrophage culture | Apigenin blocked NLRP3-driven IL-1β release, independent of CD38 | C (mechanistic, human cells) |
| Perrott 2017 (PMID 28378188, GeroScience) | Human fibroblast culture, 3 senescence models | Suppressed SASP cytokines (esp. CXCL10) via IL-1α/NF-κB pathway | C (mechanistic) |
| Gradolatto 2006 (PMID 16407641, Ann Nutr Metab) | Human PK, n=11, single dose | Apigenin poorly absorbed from food; plasma Cmax ~127 nmol/L at 7.2h | B (PK only) |
| Amsterdam 2009 (PMID 19593179, J Clin Psychopharmacol) | RCT, n=57, GAD patients, 8 wk | Chamomile extract significantly reduced anxiety (HAM-A) vs placebo (P=0.047) | B (chamomile extract, not isolated apigenin) |
| Zick 2011 (PMID 21939549, BMC Complement Altern Med) | RCT, n=34, chronic insomnia, 28 days | No significant improvement in sleep-diary measures vs placebo | B (null result, chamomile extract) |
← Swipe for more columns →
Consensus: Tier C. What we know: apigenin has plausible, cell-culture-verified anti-inflammatory and SASP-suppressing activity, plus one solid rodent paper on CD38/NAD+, plus a human PK study confirming absorption is real but limited. What we don't know: whether isolated oral apigenin at supplement doses (typically 50 mg) does any of this in a living human. The two human RCTs that exist used whole chamomile extract — a different exposure — and even those disagree (anxiety: positive; insomnia: null).
Where apigenin disappoints
- No human trial of isolated apigenin exists. The NAD+/CD38 story is mouse-liver and cell-culture; the two human RCTs used whole chamomile extract, not the supplement — and they even disagree (anxiety improved, insomnia null). - It won't move NAD+ like NMN/NR. The CD38-inhibition rationale is real in rodents but unverified in people; don't expect lab-measurable NAD+ changes from apigenin alone. - Poor absorption. Human PK shows food-form apigenin reaches only low nanomolar plasma levels — a real ceiling on whatever the mechanism could do.
Should you start apigenin?
Is your primary goal a mild evening anxiolytic/sedative effect?
Reasonable to trial, understanding the RCT evidence is for chamomile extract, not isolated apigenin — reassess subjective sleep/anxiety at 4 weeks
node | Are you already running an NMN/NR-based NAD+ stack and want a CD38-inhibition rationale on top?
Low-cost addition with a real but rodent-only mechanistic case — do not expect it to move NAD+ labs the way NMN/NR do
The unique case for apigenin (CD38/NAD+, SASP) is preclinical — spend on Tier A/B compounds first
Taking benzodiazepines, other GABAergic sedatives, or with a hormone-sensitive condition — apigenin has reported mild estrogenic/aromatase-inhibiting activity in vitro; get physician clearance
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 25–50 mg/day | No dedicated human dose-finding trial exists for isolated apigenin — this reflects common commercial supplement dosing, not a trial-derived figure |
| Form | Standardized apigenin extract (not raw chamomile, which delivers a much lower and more variable dose) | Gradolatto 2006 shows food-form apigenin is poorly absorbed regardless |
| Timing | PM | GABA-A binding supports evening use if the goal is sedation |
| Duration before reassessing | 4–8 weeks | Matches the chamomile RCT windows (8 wk for anxiety, 4 wk for insomnia) |
Week-one compliance checklist
- [ ] Confirm the label states isolated/standardized apigenin content, not just "chamomile extract"
- [ ] Log baseline sleep quality or anxiety (simple 1–10 scale) before the first dose
- [ ] Take in the evening, consistent timing night to night
- [ ] Cross-check any benzodiazepine, sedative, or hormone-sensitive medication before starting
Add apigenin to your stack
Apigenin pairs conceptually with NMN or NR as a CD38-inhibition layer on an NAD+-restoration stack — see how it scores alongside better-evidenced NAD+ precursors.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Subjective sleep quality / anxiety (1–10) | Trending toward improvement | Baseline, weekly | No change at 4–8 wk → the null insomnia RCT may be the more applicable result for you |
| Daytime sedation / grogginess | Absent | Daily | Persistent → reduce dose or discontinue |
| NAD+ (if already tracking on an NMN/NR stack) | No expected independent movement from apigenin alone | With existing NAD+ stack testing | Do not attribute NAD+ changes to apigenin specifically — no human data isolates its contribution |
← Swipe for more columns →
Anxiety (HAM-A, chamomile extract)
Elevated
Sleep diary (chamomile extract)
Poor
Anxiety (HAM-A, chamomile extract)
Significant reduction (Amsterdam 2009)
Sleep diary (chamomile extract)
No significant change (Zick 2011)
Track it honestly
Log a baseline sleep/anxiety score before starting apigenin and retest at 4–8 weeks — the human evidence is thin enough that your own log matters more than usual here.
Open Labs hubSafety, red flags, and contraindications
- Generally well tolerated at typical 25–50 mg supplement doses — chamomile, its dietary source, has a long history of food and tea use.
- Sedation is the point, but also the caveat — avoid driving or operating machinery until you know your response.
Do not self-start without clearance
- GABAergic/sedative stacking — apigenin binds the GABA-A benzodiazepine site; combining with benzodiazepines, Z-drugs, other sedative supplements, or alcohol can compound sedation.
- Mild aromatase-inhibiting / estrogenic activity in vitro — theoretical relevance for hormone-sensitive conditions (certain breast, ovarian, or prostate cancers); no human safety data rules this in or out, so get physician clearance if this applies to you.
- CYP and P-gp interactions — apigenin inhibits several CYP enzymes and P-glycoprotein in vitro; consult a physician before combining with narrow-therapeutic-index medications.
- Pregnancy and nursing — avoid supplemental (above-dietary) doses; safety not established.
- No dedicated interaction studies exist for apigenin combined with other TNiC compounds — evaluate additively with other CD38/NAD+ or anti-inflammatory compounds rather than assuming independent effects.
What would change this grade. Apigenin is C. A human trial dosing isolated apigenin and measuring NAD+, CD38 activity, or an inflammatory/senescence endpoint would move it — right now four disconnected literatures (mouse metabolism, human immune-cell culture, fibroblast culture, whole-chamomile RCTs) converge on the molecule without a dedicated human dataset.
Who should skip apigenin
- Anyone wanting a proven NAD+ booster — NMN/NR have the human data apigenin lacks; use those. - People on benzodiazepines, Z-drugs, other sedatives, or regular alcohol — apigenin binds the GABA-A benzodiazepine site; sedation compounds. - Hormone-sensitive conditions — apigenin has in-vitro estrogenic/aromatase activity with no human safety data; get clearance.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| NMN | NMN supplies the NAD+ precursor; apigenin's CD38-inhibition rationale is to slow the drain on the same pool — complementary in mechanism, unverified in combination | NMN module |
| NR | Same NAD+-restoration logic as NMN via a different entry point in the salvage pathway | NR module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Benzodiazepines / Z-drugs / alcohol | Additive GABA-A sedation | Don't stack sedatives; avoid driving until you know your response |
| Narrow-therapeutic-index CYP/P-gp drugs | Apigenin inhibits several CYP enzymes and P-gp in vitro | Physician review before combining |
| Other flavonoid CD38 inhibitors (e.g. quercetin) | Overlapping unproven NAD+-preservation rationale | Evaluate as shared, not additive; don't pay twice |
Personal results template
My Apigenin results log
| Date | Week | Dose | Sleep quality (1–10) | Anxiety (1–10) | Daytime grogginess | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 4 | 25–50 mg PM | — | — | — | Insomnia-trial-matched checkpoint |
| YYYY-MM-DD | 8 | 25–50 mg PM | — | — | — | Anxiety-trial-matched checkpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Sleep quality or anxiety trending down/better without daytime grogginess. - No effect: No change at 8 weeks with confirmed nightly compliance — consistent with the null chamomile-insomnia RCT; reasonable to stop. - Stop and reassess: Persistent daytime sedation, or any new symptom while on an interacting medication.
Log your experiment
Apigenin's human evidence is thinner than most compounds in this library — track it against a defined baseline so you can tell a real effect from placebo.
Personal journeyReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.